|Aligos Therapeutics Inc., of South San Francisco||ALG-000184||Class II capsid assembly modulator||Hepatitis B virus infection||Dosed first subject in the study testing the safety and pharmacokinetics of single and multiple ascending doses of ALG-000184 in healthy volunteers and antiviral activity in patients|
|Axovant Gene Therapies Ltd., of New York||AXO-Lenti-PD||Gene therapy||Parkinson’s disease||At 6 months post-treatment, all 4 patients in the second dose cohort had improvement in Hauser diary “Good on time” and “off time” changes from baseline; 2 evaluable patients had improvement in UPDRS Part II and Part III “OFF” score; first patient had a 23-point improvement from baseline to 12 months in UPDRS Part III “off” score at 12 months|
|Bellicum Pharmaceuticals Inc., of Houston||BPX-601||GoCAR-T candidate||Pancreas tumor||In cohort 5C, 3 patients had stable disease and 1 patient had progressive disease; there was evidence of rimiducid-mediated CAR-T cell activation|
|Eli Lilly and Co., of Indianapolis||Olumiant (baricitinib)||JAK inhibitor||Alopecia areata||After 36 weeks of treatment in the BRAVE-AA1 study, 33.3% and 51.9% of patients taking 2 mg and 4 mg of the drug, respectively, had 20% or less of scalp hair loss, compared to 3.6% of patients taking placebo (p=0.016 and p=0.001, respectively)|
|Biolinerx Ltd., of Tel Aviv, Israel||Motixafortide||CXCR4 inhibitor||Hematopoietic stem cell transplantation||Independent data monitoring committee recommended stopping enrollment based on statistically significant evidence favoring treatment with motixafortide; data from the 122 enrolled patients are expected in the first half of 2021|
|Cerevel Therapeutics LLC, of Boston||Tavapadon||Dopamine D1/D5 receptor partial agonist||Parkinson’s disease||First patients dosed in 3 27-week studies; Tempo-1 is testing fixed doses of the drug; Tempo-2 tests flexible doses; Tempo-3 tests drug plus levodopa in late stage patients; primary endpoint of TEMPO-1 and -2 is the change from baseline in the MDS-UPDRS Part II and Part III combined score; primary endpoint of TEMPO-3 is the change from baseline in total daily “on” time without troublesome dyskinesia|
For more information about individual companies and/or products, see Cortellis.